RxDoctor Payments Data

Sabrina Carter

Family · Price, UTNPI 1558628313

Payments from drug & device makers

$1,437in general payments, 2019–2025

Across 65 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$317
  • Alkermes, Inc.$289
  • Otsuka America Pharmaceutical, Inc.$135
  • Johnson & Johnson$125
  • Janssen Scientific Affairs, LLC$115
  • Braeburn Inc.$107
  • plus $350 from 8 others

What the payments were for

  • Consulting fees$1158%
  • Food & beverage$1,27389%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,437 in reported general payments places this provider in the 75th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$11,339
Medicare patients
26
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$55,317
Abilify MaintenaAripiprazole19$50,714
AristadaAripiprazole Lauroxil14$42,601
Aripiprazole81$12,163
TrintellixVortioxetine Hydrobromide13$5,997
Clozapine138$5,842
Risperidone OdtRisperidone11$3,428
Olanzapine85$2,830
Quetiapine Fumarate171$2,720
Olanzapine OdtOlanzapine26$2,233
Escitalopram Oxalate84$1,499
Oxcarbazepine26$1,412
Trazodone Hcl76$1,364
Lamotrigine93$1,182
Sertraline Hcl60$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$125$55,31716 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$135$50,71419 claims
Alkermes, Inc.Aristada$289$42,60114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,460 family providers in Utah.

Other family in Price

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →